Premium
A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV‐positive patients
Author(s) -
Busti AJ,
Tsikouris JP,
Peeters MJ,
Das SR,
Canham RM,
Abdullah SM,
Margolis DM
Publication year - 2006
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/j.1468-1293.2006.00382.x
Subject(s) - medicine , qt interval , atazanavir , ritonavir , confidence interval , prospective cohort study , cardiology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load , virology
Background Atazanavir (ATV), an HIV protease inhibitor (PI) that may be preferred for the treatment of HIV‐infected patients with cardiovascular comorbidities because of its favourable effects on plasma lipids, has been associated with cardiac rhythm disturbances. Objective To quantify the effect of ATV on corrected QT (QTc) and QTc dispersion (QTd), markers of the potential for cardiac dysrhythmia, in patients switching from other PIs to ATV. Methods In this prospective, single‐centre, open‐label study, 12‐lead electrocardiograms were performed for subjects at baseline, 2 h after the first dose of ATV, and 1 month after initiation of ATV. Results Twenty‐one patients (19 received ritonavir‐boosted ATV) completed the study. There was a trend towards an increase in the QTc at 2 h after the first dose [mean±standard deviation 3.19±8.0 ms; 95% confidence interval (CI) −0.47 to 6.85 ms; P =0.084]. There was no difference between QTc values at baseline and at 1 month (−1.5±8.75 ms; 95% CI −5.50 to 2.46; P =0.43). There was a nonsignificant decrease in the QTd between baseline and 2 h (−5.1±15.19 ms; 95% CI −13.22 to 2.96; P =0.197) and between baseline and 1 month (−0.61±15.04 ms; 95% CI −8.1 to 6.87; P =0.865). A significant increase in the PR interval (7.4±10.7 ms; 95% CI 2.5 to 12.25 ms; P =0.005) was observed at 1 month. Conclusions The use of ATV did not result in increases in the QTc interval or QTd. However, PR interval monitoring may be warranted in patients with underlying heart block or those treated with atrioventricular nodal blocking agents.